An individual urinary proteome analysis in normal human beings to define the minimal sample number to represent the normal urinary proteome by Xuejiao Liu et al.
Liu et al. Proteome Science 2012, 10:70
http://www.proteomesci.com/content/10/1/70RESEARCH Open AccessAn individual urinary proteome analysis in normal
human beings to define the minimal sample
number to represent the normal urinary
proteome
Xuejiao Liu1†, Chen Shao2†, Lilong Wei3, Jindan Duan4, Shuzhen Wu4, Xuewang Li1, Mingxi Li1* and Wei Sun4*Abstract
Background: The urinary proteome has been widely used for biomarker discovery. A urinary proteome database
from normal humans can provide a background for discovery proteomics and candidate proteins/peptides for
targeted proteomics. Therefore, it is necessary to define the minimum number of individuals required for sampling
to represent the normal urinary proteome.
Methods: In this study, inter-individual and inter-gender variations of urinary proteome were taken into
consideration to achieve a representative database. An individual analysis was performed on overnight urine
samples from 20 normal volunteers (10 males and 10 females) by 1DLC/MS/MS. To obtain a representative result of
each sample, a replicate 1DLCMS/MS analysis was performed. The minimal sample number was estimated by
statistical analysis.
Results: For qualitative analysis, less than 5% of new proteins/peptides were identified in a male/female normal
group by adding a new sample when the sample number exceeded nine. In addition, in a normal group, the
percentage of newly identified proteins/peptides was less than 5% upon adding a new sample when the sample
number reached 10. Furthermore, a statistical analysis indicated that urinary proteomes from normal males and
females showed different patterns. For quantitative analysis, the variation of protein abundance was defined by
spectrum count and western blotting methods. And then the minimal sample number for quantitative proteomic
analysis was identified.
Conclusions: For qualitative analysis, when considering the inter-individual and inter-gender variations, the
minimum sample number is 10 and requires a balanced number of males and females in order to obtain a
representative normal human urinary proteome. For quantitative analysis, the minimal sample number is much
greater than that for qualitative analysis and depends on the experimental methods used for quantification.
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Human urine is mainly composed of shed cells, debris,
and secreted components from the urinary tract as well as
blood components that have passed through glomerular
filtration and renal tubule reabsorption. Therefore, urine
contains useful information not only regarding the kidney
and urinary tract, but also about more distant organs.
Analysis of the urinary proteome could aid the discovery
of biomarkers for both urogenital and systemic diseases.
Moreover, compared to serum, human urine is relatively
simple and easy to collect, which makes urinary proteome
analysis an attractive approach in clinical proteomics
research.
Because inherent and environmental factors may influ-
ence the components of the urinary proteome, the bio-
logical and technical variations are important issues for
urinary proteome research. Many groups [1-6] have con-
tributed data regarding this issue and found that (1) a
considerable degree of variation can be found in intra-
day (collection from one volunteer at different daily time
points), intra-individual (collection from one volunteer
on different days), and inter-individual (collection from
different volunteers) samples; (2) the variation of five
intra-day samples (first morning, second morning, 24 h,
random, and water loading void) was similar; (3) the vari-
ation of intra-individual samples was less than that of
inter-individual samples; and (4) technical variation was
less than biological variation. Although great variations
have been found in different urinary samples, a number of
urinary proteins were demonstrated to be consistently
present in urine samples collected at different time points
and from different individuals [4]. Moreover, Nagaraj
et al. used healthy volunteers to construct a common
dataset of 500 urinary proteins [5]. Taken together, the
findings to date indicate that the urinary proteome is rela-
tively stable and a good source for disease biomarkers.
Since the first urinary proteome analysis was published
in 2001 [7], many clinical urinary proteome differential
analyses have been reported, including analyses of sam-
ples from urogenital diseases (kidney transplantation [8],
diabetic nephropathy [9], obstructive nephropathy [10],
bladder cancer [11], prostate cancer [12], and others)
and non-urogenital diseases (hematopoietic stem cell
transplantation [13], coronary artery disease [14], and
others).
A urinary proteome database from normal human
samples plays an important role in biomarker discovery.
In the discovery stage, a database could be used as a
control for a disease group. In the validation stage, the
candidate proteins/peptides could be selected from the
database for MS-based or immuno-based validation.
Many groups have analyzed the normal human urinary
proteome using various approaches and have identified
more than 2500 urinary proteins to date [15]. Analysesof the normal urinary proteome have usually analyzed
pooled or individual samples from several volunteers
[15-17]. However, due to the variations in the urinary
proteome, it is still unknown whether these data repre-
sent the true pattern of the normal urinary proteome. If
the sample number was less than the minimal number
required for a representative database in a group, then
an analysis may only represent the pattern of selected
individuals and not the entire group, which would be
misleading for subsequent studies. Therefore, to obtain a
representative urinary proteome, it is necessary to define
the minimal urinary sample number needed. To the best
of our knowledge, such an analysis has not been con-
ducted to date.
In this study, inter-individual and inter-gender varia-
tions were taken into consideration to achieve a repre-
sentative urinary proteome. An individual urinary
proteome analysis of 10 male and 10 female normal
overnight samples from healthy volunteers was used to
define the minimal samples number required. Because
the data-dependent acquisition mode in LC/MS/MS
analysis is biased against low abundance proteins [18],
replicate experimental strategies are often used to obtain
a comprehensive analysis [18-20], and therefore this
strategy was also adopted for this study. To determine
how many runs are necessary to obtain a comprehensive
result for one urine sample by 1DLC/MS/MS, a pooled
sample from ten male samples was analyzed with forty
runs. Based on these calculations, 10 male and 10 female
urinary samples were then analyzed by replicate 1DLC/
MS/MS. For qualitative analysis by intra-gender and
inter-gender analysis, the minimal sample number for
male, female, and normal groups was estimated. For
quantitative analysis, the variation of protein abundance
was defined by spectrum count and western blotting
methods. And then the minimal sample number for
quantitative proteomic analysis was estimated. The over-
all workflow is shown in Figure 1.
Materials and methods
Apparatus
An LTQ XL mass spectrometer was purchased from
Thermo-Fisher (San Jose, CA). A 1200 nano-HPLC sys-
tem was obtained from Agilent (Foster, CA). An AD-
VANCE CaptiveSpray source for Thermo and C18
reverse phase capillary column was purchased from
Michrom Bioresources (Auburn, CA). The microwave
oven used in this study was solid-state Whirlpool model
VIP271 (Shanghai, China), and the maximum output
power was 850 W.
Reagents
Deionized water from a MilliQ RG ultrapure water sys-
tem (Bedford, MA) was used at all times. HPLC grade
Figure 1 The overall workflow of this study. Pooled male
samples were analyzed in replicate to define the minimal 1DLC/MS/
MS number for a comprehensive analysis. After validating the
analytical completeness in 10 males and 10 females, the minimal
sample size in a male/female group was defined. Within a group,
the minimal sample size and the ratio of males and females was
further investigated.
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bonate, iodoacetamide, dithiothreitol (DTT), sequencing
grade modified trypsin, and protease inhibitor phenyl-
methylsulfonyl fluoride (PMSF) were purchased from
Sigma-Aldrich (St. Louis, MO).
Urine collection
Overnight urine samples were collected from twenty
consenting individuals, including 10 males and 10
females (average age 28 and 31 y, respectively). The
donors had no acute or chronic illnesses and were not
taking any prescription or over-the-counter medications.
No female was menstruating at the time of urine collec-
tion. Each specimen was collected in 250 mL conical
tubes. The samples were immediately acidified to pH 2.7
with hydrochloric acid and then cooled to 4 °C to pre-
vent bacterial growth and proteolysis.
Acetone precipitation
All procedures were performed at 4 °C. Urine samples
were centrifuged at 5,000 x g for 30 min and the pellets
were removed. The supernatants were then precipitated
with 75% v/v acetone for 16 h followed by centrifugation
at 12,000 x g for 30 min. The pellets were resuspended
in lysis buffer (7 M urea, 2 M thiourea, 50 mM Tris, and
50 mM dithioerythritol) and subjected to protein quanti-
tation by the Bradford method. One pooled male sample
was mixed using ten male samples with an “equal
amounts of protein” criterion.
Protein digestion
Each sample was digested with trypsin as previously
described [21]. Briefly, each sample was reduced withDTT by heating at 100 °C for 5 min and then alkykated
with iodoacetamide at room temperature in the dark for
45 min. The samples were then digested with trypsin
(1:50) for 1 min under microwave irradiation at 850 W
using the following method: samples were placed into
1.5 mL polypropylene vials and a container with 1,000
mL of water was placed beside the sample vials to ab-
sorb the extra microwave energy. The microwave oven
was turned on for 1 min. After microwave irradiation,
the vials were removed from the microwave oven and
lyophilized to near dryness.
1DLC/MS/MS
All lyophilized samples were redissolved in 0.1% formic
acid (buffer A) at a concentration of 5 mg/mL before
MS analysis. All peptide mixtures were analyzed on a re-
verse phase C18 capillary LC column from Michrom
Bioresources (100 μm x 150 mm, 3 μm, 0.5 μL/min).
The elution gradient was 5-30% buffer B (0.1% formic
acid, 99.9% ACN; flow rate, 0.5 μL/min) for 100 min.
Eluted peptides were analyzed by an LTQ XL electro-
spray ion trap mass spectrometer. Ions were detected in
a survey scan from 400 to 2000 amu followed by 10
data-dependent MS/MS scans (1 μscan each, isolation
width 2 amu, 35% normalized collision energy, dynamic
exclusion for 90 s) in a completely automated fashion.
Western blot analysis
Western blots were performed for three proteins: alpha
1 antitrypsin, ceruloplasmin, and beta-2-microglobulin
to confirm the variation in urine. For each protein, 16
normal human overnight urine samples (10 females and
6 males) were used. A urine sample from a stage IV dia-
betic nephropathy patient was used as a control. Thirty
micrograms urine protein from each urine sample after
acetone precipitation was separated on a 4-12%
NuPAGE gel (Invitrogen). Proteins were then transferred
to polyvinylidene difluoride (PVDF) membranes (Milli-
pore, USA). The membranes were blocked for 1 h at
room temperature in Tris-buffered saline (TBS) with 5%
skim milk, and then incubated overnight at 4 °C in a 1%
milk solution containing mouse monoclonal anti-alpha 1
antitrypsin (SERPINA1) antibody (1:1000, ab9400,
Abcam), mouse monoclonal anti-ceruloplasmin antibody
(1:1000, ab51083, Abcam), and rabbit monoclonal anti-
beta-2-microglobulin antibody (1:1000, ab15976,
Abcam), respectively. The membranes were washed
three times for 5 min with TBST (Tris-buffered saline
with 0.05% Tween-20), and then incubated with horse-
radish peroxidase-labeled goat anti-mouse or mouse
anti-rabbit IgG secondary antibodies (diluted 1:5000,
Abcam) at room temperature for 3 h. After washing
three times for 5 min each in TBST, the membrane was
visualized with an ECL detection kit (Millipore, Bedford,
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(Millipore). Quantification of protein bands was per-
formed for each sample by determining the relative op-
tical density (ImageJ; National Institutes of Health,
Bethesda, MD).
Data processing
MS/MS spectra were extracted from raw files requiring
a minimum of 50 signals with an intensity of at least 1 x
105 U. Extracted MS/MS spectra were automatically
assigned to the best-matching peptide sequences using
the SEQUEST algorithm [22] and SEQUEST Browser
software package Bioworks 3.3.1 SP1. SEQUEST
searches were performed on a PC against an IPI human
protein database (v3.70, released on 6th September,
2010) [23] containing 87,069 protein sequences down-
loaded as FASTA-formatted sequences from the Website
of the European Bioinformatics Institute (http://www.
ebi.ac.uk/IPI/). To increase search speed, the protein
database was preprocessed to create a binary database
containing all possible tryptic peptides. A static modifi-
cation of +57 Da on cysteine residues was used. The
peptide mass search tolerance was set to 1.4 Da. Because
the number of methionine is relatively few in the data-
base and adding a variable modification maybe signifi-
cantly increase random match, especially for low
resolution instrument (such as LTQ XL used in the
work), therefore we did not use the variable modification
of methionine oxidation to achieve more accurate data-
base searching results.
Stringent SEQUEST filter criteria were used and
included the following: (1) DeltaCn score of at least 0.2;
(2) Rsp of 1; and (3) the XCorr cutoff was adjusted to
maintain the average false positive rate of all datasets at
approximately 1%, leading to the following thresholds:
1.8, 2.8, and 3.3 for single, double, and triple-charged
peptides, respectively.
To reduce redundancy in protein identification, pep-
tides identified from tandem spectra were reassigned to
proteins using the following procedure: (1) all peptides
identified by MS/MS spectra were searched against pro-
tein databases to define whether each peptide was
unique or shared (i.e., whether the peptide appeared in a
single protein or in multiple proteins); (2) a protein
identified by unique peptide(s) was marked as a single
protein, and any peptide shared with this protein was
also assigned to the protein; (3) the remaining shared
peptides were redistributed to group proteins using the
Occam’s razor constraint [24], which states that the least
number of proteins yields the most peptide sequences;
and (4) in a group of proteins identified by the same
shared peptides, the longest protein and/or the protein
annotated by the Swiss-Prot or Trembl databases was
chosen to represent the group.Statistical analysis
To estimate the number of newly identified proteins
along with the increased run/sample numbers, computer
simulations were conducted by randomizing the order of
each run/sample to be added to the existing run/sample
pool. Means and standard deviations of the newly identi-
fied rates were calculated based on 5000 simulations to
plot all of the saturation curves presented in this study.
To further study the intra- and inter-gender variation,
the overlap rate of identified proteins was calculated for
each pair of samples. Hierarchical clustering analysis was
also applied to this qualitative data. The distance be-
tween two samples was represented by one minus the
overlap rate and the Ward’s minimum variance method
was used as the clustering method. All of the statistical
analyses were performed using the R program.
Quantitative analysis and sample size calculation
Spectrum counts of proteins were calculated for the
quantitative analysis. Since the LTQ XL mass spectrom-
eter used in this study is of relative low sensitivity, only
proteins that were reproducibly identified in at least 80%
of the total 291 MS/MS runs were included in this study.
To determine the minimal sample size needed to detect
protein expression differences with a given level of stat-
istical significance, the pwr.t.test function in the pwr
package of the R program was used for power calcula-
tion of the two-sample t test [25].
Results
Overall identification of 21 samples
To achieve a comprehensive analysis of the urinary
proteome by 1DLC/MS/MS, a replicate analysis was per-
formed for 21 samples (one pooled male sample, 10
male samples, and 10 female samples). A total of 40 runs
were performed for the pooled male sample, and an
average of 12.5 runs were performed for each male/fe-
male sample, yielding a total of 291 runs for this study.
To obtain high confidence results, a reverse database-
searching method was used to evaluate random matches.
All raw data were searched against the reverse database
to estimate the false-positive rate (the false-positive rate
= 2 x [spectrum count in reverse database]/[spectrum
count in reverse database + spectrum count in forward
database] x 100 [%]) [26]. The average false-positive rate
of 291 results was approximately 1% based on a strin-
gent SEQUEST criterion (Additional file 1).
In all, a total of 867 proteins, 2,804 peptides, and
152,449 spectra were identified from 21 samples, and an
average of 219 proteins, 520 peptides, 7,259 spectra were
found in each sample (Table 1, detailed information in
Additional files 1 2 3 4). The inter-run overlap rates for
protein and peptide identification were 74.12% and
71.23%, respectively, indicating a good reproducibility of
Table 1 The identification and inter-run overlap rates for 21 urinary samples
Protein Peptide Spectrum Runs
Mean±SD Total Overlap rate (%) Mean±SD Total Overlap rate (%) Mean±SD Total
Pooled male sample 86±6 232 76.14±3.49 167±11 457 72.8±2.75 412±39 16,524 40
Male1 94±6 188 77.17±3.04 268±10 481 79.09±1.99 921±66 11,054 12
Male2 122±4 201 82.31±2.8 324±8 556 79.59±3.07 863±26 10,366 12
Male3 120±9 225 79.62±2.73 248±23 494 76.02±3.63 785±56 10,213 13
Male4 150±9 285 77.89±3.43 395±20 803 74.35±4.58 985±55 13,801 14
Male5 73±5 129 79.36±3.12 196±10 374 75.72±2.83 551±28 5519 10
Male6 75±3 132 78.17±2.64 203±10 363 76.89±1.91 785±40 7072 9
Male7 82±5 160 75.21±3.3 162±11 329 71.9±2.24 392±25 3920 10
Male8 82±4 162 74.34±3.2 164±8 336 71.09±2.56 366±26 3294 9
Male9 99±3 197 76.36±2.59 212±8 438 73.15±2.54 513±24 5647 11
Male10 83±5 167 77.23±2.38 192±8 397 73.82±1.78 417±14 5013 12
Female1 101±4 243 69.83±2.85 237±10 558 72.21±1.78 529±22 7941 15
Female2 97±5 212 69.6±3.19 245±10 565 67.85±2.52 446±23 4908 11
Female3 106±8 226 68.99±2.91 227±11 550 61.68±2.19 343±19 3439 10
Female4 104±4 217 72.42±2.61 197±9 479 67.75±1.77 358±14 3942 11
Female5 103±9 254 67.72±4.07 218±19 588 63.89±4.33 415±37 6235 15
Female6 79±4 180 75.13±2.74 152±8 363 70.85±2.51 333±14 5336 16
Female7 141±7 357 70.55±2.36 336±16 867 69.56±1.71 581±31 9310 16
Female8 119±7 297 68.27±2.84 267±15 723 64.17±2.38 443±23 6657 15
Female9 103±6 238 70.37±3.3 198±17 506 66.88±3.82 350±31 4912 14
Female10 120±5 296 69.97±3.75 264±13 701 66.67±3.98 459±22 7346 16
Total 867 2,804 152,449 291
Figure 2 The newly identified protein/peptide percentage
versus run number in pooled male samples. Each point
represents the percentage of newly identified protein/peptides
obtained from an additional run. When the run number reached six,
the percentage was 4.9%, indicating six 1DLC/MS/MS runs may
obtain 95% analytical completeness in one sample.
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1DLC/MS/MS strategy was used to improve detection
sensitivity and to balance the high-abundance protein
identification bias of the data-dependent acquisition
mode. Compared with a single run, more than 2-fold
protein/peptides were identified with the replicate strat-
egy in 21 samples, providing more information on the
samples for further analysis (Table 1).
The minimal 1DLC/MS/MS number for a comprehensive
analysis of one urine sample
To estimate the minimal 1DLC/MS/MS number of runs
required for a comprehensive analysis using the present
instrumentation and protein database, replicate 1DLC/
MS/MS runs were statistically analyzed to determine at
which point additional experiments produced fewer
newly identified proteins. A total of 40 runs were per-
formed in a pooled male sample and identified a total of
232 proteins and 457 peptides, with an average inter-run
overlap rate of 76.14% (Table 1).
To estimate the percentage of newly identified pro-
teins by increasing replicate run number, a saturation
curve was plotted by computer simulation as described
in the Method section. Figure 2 showed that approxi-
mately 76% of identified proteins in any run could beconfirmed by any second run and 24% of proteins
remained unconfirmed. Adding a third run decreased
the newly identified protein percentage to 12%. After six
runs, this number decreased to 4.9%, and after 25 runs,
Figure 3 The comparison of average protein/peptide overlap
rate from intra-run, intra-gender, and inter-gender analyses.
The difference in the overlap rates of intra-run, intra-gender, and
inter-gender analyses indicated there was intra- and inter-gender
individual variation in the urinary proteome.
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though 25 1DLC/MS/MS analyses provided more infor-
mation than six analyses (208 proteins vs. 144 proteins,
respectively), approximately 3-fold more experiments
had to be performed, which is not suitable for analyzing
larger numbers of samples. Therefore, six 1DLC/MS/MS
analyses were empirically chosen as the point for the
subsequent individual urinary proteome analyses. The
newly identified peptide percentage with the increase in
the number of runs was also plotted and showed almost
the same trend as that of proteins (Figure 2).
The analytical completeness of 20 urine samples
To define the minimal sample number for a group urin-
ary proteome analysis, it is necessary to perform a com-
prehensive analysis of each sample. The term “analytical
completeness” was used to describe the completeness of
a urinary proteome obtained by LC/MS/MS analysis for
one sample. The percentage of analytical completeness
represented the percentage of newly identified protein/
peptides gained by an additional run.
Overnight urine samples from 10 males and 10
females were analyzed by replicate 1DLC/MS/MS and
each sample was subjected to at least nine 1DLC/MS/
MS analyses. At a 1% false positive rate, a total of 836
proteins and 2,396 peptides (an average of 213 proteins
and 522 peptides in each sample) were identified in
these 20 samples, and the average inter-run overlap rate
was 74.03% (Table 1).
To validate the analytical completeness of the 20 sam-
ples, the newly identified protein/peptide percentage was
calculated as a function of run number. The results from
the 20 samples (Additional file 5) showed that when the
run number exceeded six, the newly identified protein/
peptide percentage decreased to less than 5%, consistent
with the male pooled sample, and at 12 and 15 1DLC/
MS/MS runs, the final newly identified protein/peptide
percentage was approximately 2%. These results indicate
that by using replicate 1DLC/MS/MS analyses (9–16
runs), more than 95% analytical completeness was
achieved for the 20 samples.
The minimal sample number for a male/female group by
qualitative analysis
Before estimating the minimal sample number for a
group, the sample number for a sub-group was defined,
which in this case was a male/female group. The intra-
gender individual variation was defined by protein/pep-
tide overlap rate analysis between the 20 samples. The
average intra-gender protein/peptide overlap rates from
10 male and 10 female samples was 58.62% and 50.71%,
respectively, which were significantly lower than that of
inter-run rates (Figure 3). These results showed that
there was intra-gender individual variation in the urinaryproteome, which were consistent with previous reports
[15,16]. The intra-gender individual variation indicated
that for a male/female group, multiple samples should
be included in order to obtain a comprehensive urinary
proteome analysis.
The 10 male or 10 female 1DLC/MS/MS results were
then used to define the minimal sample number for a
male or female group, respectively. The term “analytical
completeness” was also used to describe the complete-
ness of a group urinary proteome by multiple sample
statistical analysis. The newly identified protein/peptide
percentage was calculated as a function of sample size.
The saturation curves for male and female samples were
plotted by computer simulation. When the sample num-
ber was six, the newly identified protein/peptide percent-
age was less than 10%, and when the sample number
reached nine, the percentage decreased to less than 4%.
The results for males and females showed the same
trend (Figure 4). These data indicated that 6/9 samples
may achieve approximately 90/95% analytical complete-
ness, respectively, of a male/female group urinary
proteome.
The minimal sample number for a group by qualitative
analysis
The inter-gender individual variations were also defined
by a protein/peptide overlap rate analysis between all of
the 20 samples. The overlap rate of inter-gender samples
(49.12 and 40.02% for protein and peptide, respectively)
was significantly lower than that of intra-gender samples
(Figure 3), indicating that there was inter-gender individ-
ual variation in the urinary proteome. Moreover, a previ-
ous study [27] reported that gender-specific proteins
could be found in male samples, suggesting that when
Figure 4 The newly identified protein/peptide percentage versus sample size in 10 males (A) and 10 females (B). Each point represents
the percentage of newly identified protein/peptides obtained with an additional sample. When the sample number reached nine, the percentage
was approximately 5%, indicating that nine samples may yield 95% analytical completeness in a male/female group.
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by inter-gender sample analysis, the selected samples
should include at least one male/female sample.
Figure 5 showed that when the sample number was
six, the newly identified protein/peptide percentage was
less than 10%, and when the sample number reached 10,
the percentage decreased to less than 5%. In addition,
when the sample number was increased to 20, the newly
identified protein/peptide percentage was approximately
2%. The above results showed that 6/10 male/female
samples may contain approximately 90%/95% analytical
completeness, respectively, of a group urinary proteome.Figure 5 The newly identified protein/peptide percentage
versus sample size for 20 samples. Each point represents the
percentage of newly identified protein/peptides obtained with an
additional sample. In each point, the samples included as least one
male/female sample. When the sample number reached 10, the
percentage was approximately 5%, indicating that 10 samples may
yield 95% analytical completeness in a group.To define the inter-individual and inter-gender vari-
ation more comprehensively, further qualitative analysis
was performed. Figure 6A shows the pairwise protein
overlap rate of the 21 samples. For visualization, the
rates were color-coded. The higher overlap rates were
clearly in the intra-gender region, and the pooled male
samples had higher overlap rates with male samples.
Hierarchical clustering analysis based on the same quali-
tative data showed that the male/female samples clus-
tered together (Figure 6B). These results indicate that
the male and female urinary proteome may have differ-
ent patterns.
The minimal sample number for a group by quantitative
analysis
Quantitative analysis has been widely used in clinical urin-
ary proteomic studies. In these studies, hypothesis test
(usually t test) is commonly used to identify whether a pro-
tein expressed significantly different between the disease
and control group. Two types of error occur in a hypoth-
eses test: the false positive error α and the false negative
error β. α is also called the significance level, whereas 1- β
refers to the power of the statistical test. Controlling both
of these errors is crucial to the success of a proteomic
study. To achieve this goal, enough number of samples
must be included in the study. The minimal sample size in
each group can be calculated based on the level of vari-
ation between samples, the expected fold change, the sig-
nificance level and the statistical power [25].
In proteomic studies, typically hundreds or thousands
of proteins/peaks are needed for the hypothesis test of
their expression level. The chance of the false positive
results increases significantly when multiple hypothesis
tests are needed to be performed. Therefore false
Figure 6 Pairwise protein overlap rates and hierarchical clustering of 21 samples based on protein pattern. A: Heatmap of the overlap
rate between each sample pair. The higher overlap rates were clearly in the intra-gender region rather than in the inter-gender region. B:
Hierarchical clustering of 21 samples also based on the protein overlap rates. The male/female samples clustered together. Both results showed
that male and female urinary proteomes showed different patterns.
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analysis should be calculated and controlled to an ac-
ceptable level [28].
In this report a semi-quantitative method (spectrum
count, SC) was used to calculate the coefficient of vari-
ation (CV) between samples. Because SC was relatively
accurate for evaluating highly abundant proteins, only
proteins identified in more than 80% of the 291 LC-MS/
MS runs were included, which was a total of 31 proteins.
The median CV of these proteins was then used to cal-
culate the minimal sample number. For male, female,Table 2 The estimated minimal sample number per group for
where power is the power of statistical test, α is the significa
truly differentially expressed proteins among all of the ident
fold change power α π FDR
2 0.8 0.001 0.05 2.31%
0.8 0.005 0.1 5.33%
0.8 0.01 0.2 4.76%
0.9 0.001 0.05 2.06%
0.9 0.005 0.1 4.76%
0.9 0.01 0.2 4.26%
1.5 0.8 0.001 0.05 2.31%
0.8 0.005 0.1 5.33%
0.8 0.01 0.2 4.76%
0.9 0.001 0.05 2.06%
0.9 0.005 0.1 4.76%
0.9 0.01 0.2 4.26%and normal groups, the median CV was 66.2%, 58.2%,
and 70.6%, respectively. The minimal sample number at
a 5%FDR is shown in Table 2. When the fold change
was 2, the average minimal sample number was 16, 13,
and 18 for the male, female, and normal groups, respect-
ively. However, when the fold change was 1.5, the aver-
age minimal sample number increased to 58, 46, and 66
for these groups, respectively.
To estimate the minimal sample number for proteins
with lower abundance, western blot was used to measure
three proteins (alpha 1 antitrypsin, ceruloplasmin, andquantitative analysis based on spectrum count method,
nce level, and π refers to the estimated proportion of
ified proteins
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http://www.proteomesci.com/content/10/1/70beta-2-microglobulin). These three proteins were identi-
fied in less than 40% of the LC-MS/MS runs and the
CVs of SC were 170.6%, 279.1%, and 222%, respectively.
However, based on the western blot analysis (Figure 7),
the CVs were 81.2%, 101.1%, and 93%, respectively, indi-
cating that quantitative western blot was more accurate
than SC for proteins with low abundance. The average
minimal sample number for these three proteins was 30
with a 2-fold change and 110 with a 1.5-fold change, in-
dicating that more samples were necessary to obtain sig-
nificant results for proteins of low abundance than those
of high abundance (Table 3).
Discussion
In recent years, clinical urinary proteomic analyses have
been widely used to discover biomarkers. A thorough
and representative urinary proteome database of normal
human samples is critically important as the background
of a disease proteome for discovery proteomics and the
source of candidate proteins/peptides for targeted pro-
teomics. Since 2001, a number of groups have addressed
this issue, and more than 2500 proteins have been iden-
tified from the normal human urinary proteome. How-
ever, there are still some important aspects that need to
be defined.Figure 7 The western blot analysis of alpha 1 antitrypsin (A),
ceruloplasmin (B), and beta-2-microglobulin (C) from 16 normal
human overnight urine samples (10 females and 6 males, N1-
N16) and one stage IV diabetic nephropathy urine sample as
control (one male, C).To construct a representative urinary proteome, it is
necessary to define the minimal sample number. Too
few samples may present individual-specific proteins
that do not represent the group pattern. Previous studies
[15-17] have used various sample numbers ranging from
one to over ten. However, because this issue has not
been thoroughly assessed, the minimal sample number
was unknown. In this study, inter-individual and inter-
gender variations were taken into consideration for
qualitative analysis to achieve a representative urinary
proteome. We used replicate LC/MS/MS analyses of 20
urine samples from healthy volunteers to define the
minimal sample number needed. The results showed
that 9 male/female samples may contain approximately
95% analytical completeness of a male/female group. For
a group, 10 samples can achieve 95% analytical com-
pleteness. Importantly, the results of this study may be
helpful for constructing a new urinary proteome data-
base or evaluating an existing database. The universal
application of these conclusions should be cautioned for
several reasons. First, technical variations factors, includ-
ing sample preparation, LC separation, mass spectrom-
eter detection, and data processing can affect the final
identification results. The conclusions of this study are
based on the results obtained with 1DLC separation and a
low sensitivity and resolution mass spectrometer (LTQ
XL). Any change in these factors, such as using an instru-
ment with high sensitivity and high resolution (i.e. Orbitrap
or TripleTOF 5600), might result in a different conclusion.
For example, in this report a total of 867 proteins were
identified with one-dimensional separation (1DLC) and
low resolution instrument (LTQ XL). Kentsis et al. [29]
identified 2362 proteins using three-dimensional separ-
ation (centrifugation, SDS-PAGE, and 1DLC) and a high
resolution instrument (LTQ Orbitrap XL). Thus, with
more separation approaches and a more accurate instru-
ment, a substantially greater number of proteins could be
identified and more useful information might be obtained.
On the other hand, it is well known that the urinary prote-
ome had great biological variation. In this study, only inter-
individual and inter-gender variations were taken into con-
sideration, and other biological variations (such as age, hor-
mone level, exercise, and others [30]) may also have a
marked impact on the results and increase the sample
number. Therefore, the conclusion presented here repre-
sents a preliminary result that may be the minimal sample
number needed. If other variation factors are included, the
minimal sample number may increase.
Another important issue regarding a normal urinary
proteome database is the quantitative information. For
clinical research, the aim is generally focused on identi-
fying disease-related biomarkers. The quantitative infor-
mation of each protein would be helpful to define
biological and technical variations so that the differential
Table 3 The estimated minimal sample number per group for five proteins based on western blot, where power is the
power of statistical test, α is the significance level, and π refers to the estimated proportion of truly differentially
expressed proteins among all of the identified proteins.
fold change power α π FDR alpha 1 ceruloplasmin beta-2
antitrypsin microglobulin
2 0.8 0.001 0.05 2.31% 26 38 33
0.8 0.005 0.1 5.33% 20 30 26
0.8 0.01 0.2 4.76% 18 26 22
0.9 0.001 0.05 2.06% 31 46 39
0.9 0.005 0.1 4.76% 25 37 31
0.9 0.01 0.2 4.26% 22 33 28
1.5 0.8 0.001 0.05 2.31% 93 143 121
0.8 0.005 0.1 5.33% 73 111 95
0.8 0.01 0.2 4.76% 64 98 83
0.9 0.001 0.05 2.06% 113 174 148
0.9 0.005 0.1 4.76% 91 139 118
0.9 0.01 0.2 4.26% 81 124 105
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http://www.proteomesci.com/content/10/1/70proteins with statistical significance in a group could be
identified. In addition, the false differential proteins
found due to the high variation in the group could be
excluded. To date, most normal urinary proteome ana-
lyses have been qualitative studies, and only the study by
Nagaraj et al. [15] provided overall quantitative informa-
tion of each protein using a peak intensity method. In
this report, we used SC and western blot to assess quan-
titative information of high and low abundance proteins,
respectively, and to estimate the minimal sample num-
ber needed for quantitative analysis. For high abundance
proteins, the average minimal sample number was 18
with a 2-fold change, and for the proteins of low abun-
dance, the number was 30 with a 2-fold change. These
results indicated that a higher minimal sample number
is required to obtain statistical significance when detect-
ing proteins of low abundance. We also attempted to es-
timate the minimal sample number using the Nagaraj
et al. [15] data. With 66% inter-individual CV, the min-
imal average sample number was 16 with a 2-fold
change and 58 with a 1.5-fold change, among all the ac-
ceptable levels of FDR and statistical power. These
results were similar to our results for proteins of high
abundance using the SC method. However, the sample
number, separation method, MS instrument, data pro-
cessing software and protein number used for quantita-
tive analysis were different between these two studies.
Considering that there were other quantitative methods,
such as iTRAQ and TMT, it is difficult to conclude that
the minimal sample number for urinary proteome quan-
titative analysis. Therefore, it is necessary to evaluate the
variations of various quantitative methods in the future
to define a proper minimal sample number for clinical
research.Our previous work [4] showed that it was hard to de-
fine the difference between the male and female urinary
proteomes, except for the identification of several male-
specific proteins. In addition, recent studies by both LC/
MS/MS [5] and 2DE [6] approaches also failed to iden-
tify these differences. In this study, the protein overlap
rates among the 21 samples and the result of hierarch-
ical clustering analysis allowed us to separate male and
female samples into two groups, indicating a difference
between the male and female urinary proteome pattern.
However, because this study was only based on 1DLC/
MS/MS analysis and low-resolution mass spectrometry,
the conclusion should be confirmed with additional
experiments before being universally applied. In
addition, considering the existence of male-specific pro-
teins, it is important that the ratio of male and female
samples is balanced when constructing a database.
The choice of pooled or individual sample was also an
important issue. Since the proteome is known to have
substantial biological variation, an appropriate number
of samples should be analyzed for proteomic analysis.
However, a few years ago the throughput of proteomic
techniques was limited, and in order to circumvent this
problem, samples were pooled [31]. Previous reports on
cell lines [32] or tissues [33,34] by 2DE showed that
pooling could reduce biological variation. On the other
hand, Diz et al. [34] as well as our previous study [4]
showed that pooling samples may lead to a loss of infor-
mation through sample dilution. In this study, the
pooled male sample was found to be clustered with male
samples and closest to the samples from Male 7–10, in-
dicating that a pooled sample may not adequately repre-
sent the pattern of all individual samples. Therefore, the
results from a pooled sample should be carefully
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http://www.proteomesci.com/content/10/1/70assessed before being applied to other experiments. In
recent years, with the application of instruments having
high sensitivity and high resolution (such as Orbitrap),
high-throughput urinary proteome analysis has become
possible. Nagaraj et al. [5] identified over 800 proteins in
a 4h 1DLC/MS/MS analysis using an LTQ Orbitrap XL.
Therefore, the use of individual samples is recom-
mended in future work.
Conclusion
With the wide application of the urinary proteome in
clinical research, the construction of a representative
and informative normal urinary proteome database has
become critically important. Considering the inter-
individual and inter-gender variation of the urinary
proteome, we used replicate 1DLC/MS/MS to analyze
10 male and 10 female samples for qualitative analysis,
and found that in order to achieve a representative urin-
ary database the minimal sample number was estimated
to be 10. In addition, the number of male and female
samples in a group had better be balanced. For quantita-
tive analysis, proteins of low abundance showed greater
variation and required more samples to obtain statistical
significance than proteins of high abundance. In
addition, different quantitative analyses exhibited differ-
ent technical variation, and therefore the minimal sam-
ple number should be evaluated in conjunction with the
quantitative method being used. With the need of quan-
titative information for each protein in a group and the
application of high sensitivity and resolution mass spec-
trometry, the high-throughput analysis of individual
urinary proteomes using different quantitative methods
would greatly benefit future clinical urinary proteome
studies.
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